Semaglutide in Australia: Research Context
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist with a half-life of approximately 7 days, enabling once-weekly dosing. It shares 94% sequence homology with native human GLP-1, modified with a C18 fatty diacid acylation at lysine-26 that confers albumin binding and protects against DPP-4 degradation. This pharmacokinetic profile — near-continuous receptor engagement for 7 days — is the basis for its sustained appetite suppression and metabolic effects.
Semaglutide has the largest and most mature clinical evidence base of any compound in the GLP-1 class. The STEP programme established it as a reference standard in metabolic research; the SUSTAIN programme characterised its glycaemic effects in type 2 diabetes; and the SELECT trial (2023) demonstrated cardiovascular benefits in non-diabetic obesity. No other GLP-1 class compound has equivalent depth of completed outcomes data as of 2026.
Why semaglutide remains the research benchmark Deepest completed Phase 3 dataset in the GLP-1 class · SELECT trial: 20% MACE reduction in non-diabetic obesity — first such evidence for any GLP-1 agonist · STEP 1: 14.9% mean weight loss at 68 weeks · Active research in Alzheimer's, addiction, NASH/MASH, heart failure as of 2026
STEP Trial Programme: Key Efficacy Data
The STEP programme (Semaglutide Treatment Effect in People with Obesity) is the pivotal dataset for semaglutide in obesity research. Key trials:
| Trial | Population | Duration | Key outcome |
|---|---|---|---|
| STEP 1 | Obesity, no T2D | 68 weeks | 14.9% mean weight loss at 2.4mg |
| STEP 2 | Obesity + T2D | 68 weeks | 9.6% weight loss (T2D population) |
| STEP 3 | Obesity + intensive lifestyle | 68 weeks | Up to 16% with lifestyle co-intervention |
| STEP 4 | Maintenance post-loss | 68 weeks | 6.9% regain after stopping vs −2.4% continued |
| SELECT | Non-diabetic obesity + CVD | ~34 months | 20% MACE reduction vs placebo |
STEP 4's discontinuation data is mechanistically significant for researchers: participants who stopped semaglutide regained approximately two-thirds of lost weight within one year, supporting the hypothesis that chronic receptor engagement is required for sustained metabolic effects. This has implications for research protocol design — particularly for protocols investigating maintenance endpoints.
Reconstitution and Dosing Reference for Australian Researchers
RetaLABS Semaglutide is supplied lyophilised. Use bacteriostatic water for reconstitution. The STEP 1 maintenance dose was 2.4mg/week; the escalation schedule used in trial was gradual, starting at 0.25mg/week.
Common research concentrations:
| Vial size | BAC water added | Concentration | Volume per 0.5mg | Volume per 1mg | Volume per 2.4mg |
|---|---|---|---|---|---|
| 5mg | 2.5 mL | 2 mg/mL | 0.25 mL | 0.50 mL | 1.20 mL |
| 5mg | 5.0 mL | 1 mg/mL | 0.50 mL | 1.00 mL | 2.40 mL |
| 10mg | 5.0 mL | 2 mg/mL | 0.25 mL | 0.50 mL | 1.20 mL |
Store lyophilised vials at −20°C. Store reconstituted solution at 2–8°C; use within 4–6 weeks. Do not freeze reconstituted solution. Rotate injection sites weekly. Use the RetaLABS reconstitution calculator for custom volumes. For full storage protocols, see the Peptide Reconstitution & Storage Guide.
How Semaglutide Compares to Newer Compounds in Australia
Semaglutide occupies a distinct position in the Australian research peptide landscape: it has the most evidence, but is no longer the most efficacious compound in the class:
| Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Best Phase trial weight loss | 14.9% (68 weeks) | 20.9% (72 weeks) | 24.2% (48 weeks) |
| Cardiovascular outcomes trial | Completed (SELECT) | Ongoing (MMO) | Ongoing (SYNERGY) |
| Phase 3 completion | Multiple completed | Multiple completed | Ongoing (TRIUMPH) |
| GI AE burden | Lower | Lower | Higher at max dose |
| Receptor targets | GLP-1R only | GLP-1R + GIPR | GLP-1R + GIPR + GcgR |
Semaglutide's research advantage is its evidence depth — it is the only GLP-1 compound with a completed cardiovascular outcomes trial in non-diabetic obesity (SELECT). For research specifically investigating cardiovascular endpoints or requiring the most established long-term safety profile, semaglutide remains the reference standard. For weight loss efficacy endpoints, newer compounds have surpassed it.
For detailed comparisons, see Retatrutide vs Semaglutide and the GLP-1 Peptides Comparison Guide.